HCA Healthcare reported strong second-quarter 2026 financial results, with revenue reaching USD 20.23 billion and earnings per share (EPS) of USD 7.59, beating analyst estimates by USD 0.03. The company's stock closed at USD 402.02 on September 8, 2026, reflecting a market capitalization of USD 87.04 billion. Management highlighted that the core business is operating at the high end of its long-term EBITDA growth range of 4% to 6%, indicating robust operational performance despite broader economic headwinds. Following the earnings release, investors focused on conference remarks regarding a shift in patient payer mix, with approximately 22,000 adjusted admissions moving from exchange coverage to uninsured status. Despite this specific operating drag related to policy changes ending enhanced premium tax credits, management affirmed that 99% of the business performed as expected or better than the prior year. This resilience underscores HCA's ability to maintain growth momentum even as reimbursement dynamics evolve. Analyst sentiment remains mixed but generally positive regarding long-term potential, with a consensus price target of USD 462.64 significantly above the current stock price. While TD Cowen and Barclays recently lowered their individual targets, the wide gap between the market price and analyst expectations suggests room for upside if execution continues to meet high standards. The company maintains a quarterly dividend of USD 0.78 per share, scheduled for payment on September 30, 2026.